DOCSLIB.ORG

Meta-Analysis of the Dose-Response Relationship of SSRI in Obsessive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meta-Analysis of the Dose-Response Relationship of SSRI in Obsessive Molecular Psychiatry (2010) 15, 850–855 & 2010 Macmillan Publishers Limited All rights reserved 1359-4184/10 www.nature.com/mp ORIGINAL ARTICLE Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder MH Bloch1, J McGuire1, A Landeros-Weisenberger1, JF Leckman1 and C Pittenger2 1Yale Child Study Center, Yale University School of Medicine, New Haven, CT, USA and 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA We sought to determine differences in efficacy and tolerability between different doses of selective serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder (OCD) using meta-analysis. We identified 9 studies involving 2268 subjects that were randomized, double-blind placebo-controlled clinical trials that compared multiple, fixed- doses of selective serotonin reuptake inhibitors (SSRIs) to each other and to placebo in the treatment of adults with OCD. Change in Y-BOCS score, proportion of treatment responders, and dropouts (all-cause and due to side-effects) were determined for each included study. Weighted mean difference was used to examine mean change in Y-BOCS score. Pooled absolute risk difference was used to examine dichotomous outcomes. Meta-analysis was performed using a fixed effects model in RevMan 4.2.8. We found that compared with either low or medium doses, higher doses of SSRIs were associated with improved treatment efficacy, using either Y-BOCS score or proportion of treatment responders as an outcome. Dose of SSRIs was not associated with the number of all-cause dropouts. Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side-effects. These results suggests that higher doses of SSRIs are associated with greater efficacy in the treatment of OCD. This SSRI efficacy pattern stands in contrast to other psychiatric disorders like Major Depressive Disorder. This greater treatment efficacy is somewhat counterbalanced by the greater side-effect burden with higher doses of SSRIs. At present, there are insufficient data to generalize these findings to children or adolescents with OCD. Molecular Psychiatry (2010) 15, 850–855; doi:10.1038/mp.2009.50; published online 26 May 2009 Keywords: serotonin reuptake inhibitors; obsessive-compulsive disorder; meta-analysis Introduction demonstrated to have superior efficacy to placebo.7 A recent meta-analysis suggested that SSRIs have a Obsessive-Compulsive Disorder (OCD) is characterized number needed to treat (NNT) to achieve treatment by obsessions (unwanted, intrusive thoughts, impulses response of 5.4 (95% CI: 3.9–8.2) when compared to or images) and compulsions (mental or physical acts placebo.7 Many OCD experts advocate the use of undertaken to relieve the anxiety of the obsession) that higher and quickly escalating doses of SSRI in the cause distress. OCD has several symptom dimensions, treatment of OCD, as compared to other conditions including hoarding, forbidden thoughts (aggression, where antidepressants are effective, such as other sexual and religious obsessions), symmetry (symmetry anxiety disorders and major depressive disorder.6,8 obsessions and counting, ordering, repeating and The American Psychiatric Association Practice arranging compulsions) and cleaning, that are stable Guidelines recommend higher target doses of SSRIs across the lifespan.1,2 OCD has a cross-sectional in the treatment of OCD than they do for depres- prevalence between 1 and 3% and is projected to sion.9,10 The clinical definitions of treatment resis- become one of the top 10 leading causes of disability tance and refractory OCD require patients to fail to worldwide within the next 20 years.3–5 experience improvement on multiple SSRI at the Cognitive behavioral therapy and pharmacotherapy maximum tolerated dose for an adequate duration (at with selective serotonin reuptake inhibitors (SSRIs) least 2 months).8 Thus OCD patients are treated with are the first-line treatments for OCD.6 SSRIs have been higher doses of SSRI compared to many other conditions before progressing to alternative or aug- Correspondence: Dr MH Bloch, Child Study Center, Yale mentation therapies However, controlled studies have University School of Medicine, PO Box 20709, New Haven, CT not consistently shown benefit from higher doses of 06520, USA. SSRIs, which may carry a higher side effect burden. E-mail: [email protected] Received 22 January 2009; accepted 13 April 2009; published Indeed, a meta-analysis of antidepressant agents in online 26 May 2009 the treatment of Major Depressive Disorder has Dose-response relationship of SSRIs in OCD MH Bloch et al 851 demonstrated a significantly increased side-effect randomized clinical trials comparing at least two burden but no improvement in efficacy with higher different fixed doses of a single selective serotonin doses.11 In OCD, some fixed-dose SSRI studies have reuptake inhibitor with each other and with placebo; demonstrated greater efficacy with higher doses (2) participants included were adults diagnosed with of SSRIs12,13 while most have not.14–19 No such Obsessive-Compulsive Disorder by explicit criteria meta-analyses have been conducted for the treatment i.e. DSM-IV or ICD-10 criteria and (3) Obsessive- of OCD. compulsive disorder symptom severity was measured The goal of this current meta-analysis was to better before and after medication treatment using the quantify the dose-response relationship of SSRI in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).20 treatment of adults with OCD. We examined double- blind, placebo-controlled, fixed-dose trials of SSRIs Outcome measures that included multiple drug dosages, to determine (1) Our primary outcome measure was mean change in Y- if higher doses of SSRI are more effective in the BOCS severity during the course of treatment. treatment of OCD compared to lower doses and (2) the Secondary outcome measures included proportion relative side effect burden of higher doses of SSRI of treatment responders (assessed by the original compared to lower doses. manuscript criteria), proportion of dropouts, and proportion of dropouts due to side effects. The latter two measures served as a proxy for medication Materials and methods tolerability. The trade-off between improved efficacy and increased side effect burden is important when Search strategy for identification of studies considering dose increases of medication. Two reviewers (JM and MHB) searched PubMed on November 1, 2008 for relevant studies using the Meta-analytic procedure used search ((serotonin uptake inhibitors or fluoxetine or All statistical analysis was performed using RevMan sertraline or paroxetine or citalopram or escitalopram 4.2.8 and specially designed spreadsheets in Micro- or fluvoxamine) and obsessive-compulsive disorder) soft Excel. Our primary outcome (mean change in and limited the search to randomized clinical trials. Y-BOCS score) was analyzed using weighted mean There was no language limitation on our search. The difference. Secondary outcome measures (proportion references of relevant review articles, (identified of treatment responders, proportion of dropouts and using the same search strategy but limited to review proportion of dropouts due to side effects) were articles), were scanned for additional eligible trials. analyzed using pooled absolute risk difference Additionally, the Food and Drug Administration (ARD). Low, medium and high dose categories of website at http://www.accessdata.fda.gov/scripts/ SSRI of each available SSRI were calculated based on cder/drugsatfda/index.cfm?fuseaction = Search.Search_ fluoxetine equivalents of SSRI medications used in Drug_Name was searched for additional unpublished previous meta-analytic studies of antidepressants and fixed dose drug trials used for FDA approval of according to the APA dose recommendations for serotonin reuptake inhibitors for OCD, using the individual SSRI in OCD.9,11 Table 1 depicts dose generic names of the medications. stratification categories of all eligible SSRIs, which were determined prior to identification of studies. Selection of studies The initial test of significance for continuous data was The titles and abstracts of studies obtained by this a one-way ANOVA. The Chi-Square Test for Trend search strategy were scrutinized by two reviewers (JM was used for dichotomous outcomes. If this initial test and MHB) to determine if they were potentially was significant (P < 0.05) then each of the SSRI dose eligible for inclusion in this review. Eligibility for categories (Low, Medium, High and placebo) was the study was based upon scrutiny of the full articles compared to each other in RevMan 4.2.8 to detect for the following inclusion criteria (1) they were significant differences. For all outcome measures, Table 1 Dose classifications for selective-serotonin reuptake inhibitors Medication Minimum (mg) Maximum (mg) Low (mg) Medium (mg) High (mg) Fluoxetine 20 80 20–30 40–50 60–80 Sertraline 50 200 50–75 100–175 200 Paroxetine 20 60 20–30 40–50 60 Fluvoxamine 150 300 50–150 200–250 300–350 Citalopram 20 60–80 20–30 40–50 60–80 Escitralopram 10 40 10–15 20–25 30–40 These dose categories were defined a priori and were calculated based on fluoxetine equivalents of SSRIs used in previous meta-analytic studies of antidepressants and according to the American Psychiatric Association dose recommendations for individual SSRIs in Obsessive-Compulsive Disorder.9,11 Molecular Psychiatry Dose-response relationship of SSRIs in OCD MH Bloch et
Load more

Recommended publications
  • A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine
    A synbiotic mixture augmented the efficacy of doxepin, venlafaxine, and fluvoxamine in mice model of depression Azadeh Mesripour1, Andiya Meshkati1, Valiolah Hajhashemi2 1Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, IRAN. 2‐ Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, IRAN. ABSTRACT Objective: Currently available antidepressant drugs have notable downsides; in addition to their side effects and slow onset of action their moderate efficacy in some individuals, may influence compliance. Previous literature has shown that probiotics may have antidepressant effects. Introducing complementary medicineproof in order to augment the efficacy of therapeutic doses of antidepressant drugs seems to be very important. Therefore the effect of adding a synbiotic cocktail in drinking water was assessed in mice model of despair following administrating three antidepressant drugs belonging to different classes. Methods: The marble burring test (MBT), and forced swimming test (FST) were used as animal model of obsessive behavior and despair. The synbiotic cocktail was administered in mice drinking water (6.25×106 CFU) for 14 days and the tests were performed on the days 7 and 14 thirty minutes after injecting the lowest dose of doxepin (1 mg/kg), venlafaxine (15 mg/kg), and fluvoxamine (15 mg/kg). Results: After 7 days of the synbiotic ingestion immobility time decreased in FST for doxepin (92 sec ± 5.5) and venlafaxine (17.3 sec ± 2.5) compared to their control group (drinking water) but fluvoxamine could decrease immobility time after 14 days of ingesting the synbiotic (70 sec ± 7.5).
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine
    Turk J Pharm Sci 2020;17(3):293-298 DOI: 10.4274/tjps.galenos.2019.94210 ORIGINAL ARTICLE A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression Sinbiyotik Karışım, Fare Depresyon Modelinde Doksepin, Venlafaksin ve Fluvoksaminin Etkinliğini Artırdı Azadeh MESRIPOUR1*, Andiya MESHKATI1, Valiollah HAJHASHEMI2 1Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Toxicology, Isfahan, Iran 2Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences, Isfahan Pharmaceutical Sciences Research Center, Isfahan, Iran ABSTRACT Objectives: Currently available antidepressant drugs have notable downsides; in addition to their side effects and slow onset of action their moderate efficacy in some individuals may influence compliance. Previous literature has shown that probiotics may have antidepressant effects. Introducing complementary medicine in order to augment the efficacy of therapeutic doses of antidepressant drugs appears to be very important. Therefore, the effect of adding a synbiotic mixture to drinking water was assessed in a mouse model of depression following the administration of three antidepressant drugs belonging to different classes. Materials and Methods: The marble burying test (MBT) and forced swimming test (FST) were used as animal models of obsessive behavior and despair. The synbiotic mixture was administered to the mice’s drinking water (6.25x106 CFU) for 14 days and the tests were performed 30 min after the injection of the lowest dose of doxepin (1 mg/kg), venlafaxine (15 mg/kg), and fluvoxamine (15 mg/kg) on days 7 and 14. Results: After 7 days of ingestion of the synbiotic mixture, immobility time decreased in the FST for doxepin (92±5.5 s) and venlafaxine (17.3±2.5 s) compared to the control group (drinking water), but fluvoxamine decreased immobility time after 14 days of ingestion of the synbiotic mixture (70±7.5 s).
    [Show full text]
  • Impact of Citalopram and Fluvoxamine on Platelet Response To
    S24_5 Impact of Citalopram and Fluvoxamine on Platelet Response to Clopidogrel, a Randomized, Double-blind, Crossover Trial Bruria Hirsh Racch1, Galia Spectre2, Ella Shai2, Amit Ritter3, David Varon2, Ronny Alcalai3 1School of Pharmacy, Hadassah Hebrew University Medical Center, Israel 2Coagulation Unit, Hematology, Hadassah Hebrew University Medical Center, Israel 3Heart Institute, Hadassah Hebrew University Medical Center, Israel Background: Selective serotonin reuptake inhibitors (SSRI) are widely used antidepressant agents. Studies have shown that use of SSRI in combination with aspirin or warfarin is associated with an increased risk bleeding, while little information is known about the interaction of SSRIs and clopidogrel. Fluvoxamine and citalopram are both SSRIs and while fluvoxamine is an inhibitor of CYP2C19 and thus might reduce the efficacy of clopidogrel, the effect of citalopram on liver metabolism is unknown. Aim: The aim was to assess the effect these two different SSRIs on platelet aggregation and on the laboratory response to clopidogrel. Methods: A randomized, double-blind, crossover study in 15 healthy volunteers comparing the antiplatelet effect of clopidogrel with and without fluvoxamine or citalopram .The response to clopidogrel was assessed by Light Transmittance Aggregometry with10µmol/L ADP and by vasodilator-stimulated phosphoprotein (VASP) phosphorylation, a measure of P2Y12 receptor reactivity. Results: Mean baseline platelet aggregation was 80.1%±3.4 and reduced to 23.5% after treatment with clopidogrel. Both fluvoxamine and citalopram had modest effect on platelet reactivity (65.8%±6.4, p=0.06 vs. baseline and 67.3%±6.3, p=0.07 vs. baseline respectively). Laboratory response to clopidogrel was significantly better in the presence of citalopram as compared to fluvoxamine both in aggregometry (23.4%±3 vs.
    [Show full text]
  • Fluvoxamine Maleate Tablets Safely and Effectively
    Highlights Of Prescribing Information hypotension or seizures (5.7). Methadone: Coadministration may produce These highlights do not include all the information needed to use opioid intoxication. Discontinuation of fluvoxamine may produce opioid Fluvoxamine Maleate Tablets safely and effectively. See full prescribing withdrawal (5.7). Mexiletine: Monitor serum mexiletine levels (5.7). information for Fluvoxamine Maleate Tablets. Ramelteon: Should not be used in combination with fluvoxamine (5.7). Theophylline: Clearance decreased; reduce theophylline dose by one-third Fluvoxamine Maleate Tablets for oral administration (5.7). Warfarin: Plasma concentrations increased and prothrombin times Initial U.S. Approval: 1994 prolonged; monitor prothrombin time and adjust warfarin dose accordingly Warning: Suicidality and Antidepressants (5.7). Other Drugs Affecting Hemostasis: Increased risk of bleeding with See full prescribing information for complete boxed warning. concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation (5.7, Increased risk of suicidal thinking and behavior in children, adolescents, and 5.9). See Contraindications (4). Discontinuation: Symptoms associated with young adults taking antidepressants for major depressive disorder and other discontinuation have been reported (5.8). Abrupt discontinuation not psychiatric disorders. Fluvoxamine Maleate Tablets are not approved for use in recommended. See Dosage And Administration (2.8). pediatric patients except those with obsessive compulsive disorder (5.1). Activation
    [Show full text]
  • Luvox and Luvox CR (Fluvoxamine)
    23 Luvox and Luvox CR (fluvoxamine) Generic name: Fluvoxamine Available strengths: 25 mg, 50 mg, 100 mg tablets; 100 mg, 150 mg sustained-release capsules (Luvox CR) Available in generic: Yes Drug class: Selective serotonin reuptake inhibitor antidepressant General Information Luvox (fluvoxamine) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of obsessive-compulsive disorder (OCD) and social aniety disorder, but not depression. The use of a medication for its approved indications is called its labeled use. In clinical practice, however, physicians often prescribe medications for unlabeled (“off-label”) uses when published clinical studies, case reports, or their own clinical experiences support the efficacy and safety of those treatments. Physicians may use Luvox for treatment of major depression, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, nocturnal enuresis (incontinence of urine) in children, and bulimia nervosa. Luvox is a serotonin-specific medication that works by blocking the reuptake of the neurotransmitter se- rotonin back into brain cells, thereby increasing its levels in the brain. OCD, depression, and other mental disorders may be caused by abnormally low levels of serotonin. This abnormality may in turn produce changes in affected areas of the brain, resulting in psychiatric symptoms such as depression or anxiety. The presumed action of Luvox and other selective serotonin reuptake inhibitors (SSRIs) is to increase serotonin levels, which may help to restore those areas of the brain to normal functioning. OCD may also be successfully treated with other SSRIs as well as the tricyclic antidepressant (TCA) Anafranil (clomipramine). Dosing Information The recommended starting dose of Luvox is 50 mg as a single bedtime dose.
    [Show full text]
  • A Meta-Analysis
    who had smoked for more than 30 years. Moreover, Key messages breast cancer will occur eight years earlier in smokers than in non-smokers. This finding could support the * Breast cancer is the commonest cancer in women throughout the world, hypothesis ofa direct carcinogenic effect oftobacco. and its incidence is increasing * It has been suggested that smoking protects against breast cancer because This study was financially supported by the Niels Jensen of an antioestrogenic effect Foundation and Hj0rring District Hospital. * This study shows, however, that women who have smoked for more than 1 MacMahon B, Trichopoules D, Cole P, Brown J. Cigarette smoking and 30 years have an increased risk ofdeveloping breast cancer urinary estrogens. NEnglJMed 1982;307:1062-5. 2 Baron JA, LaVecchia C, Levi F. The antiestrogenic effect of cigarette smoking * Moreover, smokers with breast cancer were eight years younger than in women. Amy Obstet Gynecol 1990;162:502-14. non-smokers with breast cancer 3 Petrakis NL, Maack CA, Lee RE, Jyon M. Mutagenic activity in nipple aspirates ofhuman breast fluid. Cancer Res 1980;40:188-9. 4 Hiatt RA, Fireman BH. Smoking, menopause, and breast cancer. J Natl Cancer Inst 1986;76:833-8. than those in 5 Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. included our model-for example, EpidemiolRev 1993;5:145-56. alcohol, diet, body size, and use of oral contraception 6 Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley, -have been studied extensively.' 02 The associations 1989. 7 Osler M. Danskernes rygevaner [Smoking habits of Danes].
    [Show full text]
  • ROZEREM Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Reproductive effects: Include decreased testosterone and increased These highlights do not include all the information needed to use prolactin levels. Effect on reproductive axis in developing humans is ROZEREM safely and effectively. See full prescribing information for unknown. (5.5) ROZEREM. • Patients with severe sleep apnea: ROZEREM is not recommended for use in this population. (5.6) ROZEREM (ramelteon) tablets, for oral use Initial U.S. Approval: 2005 --------------------------------ADVERSE REACTIONS------------------------------ Most common adverse reactions (≥3% and more common than with --------------------------INDICATIONS AND USAGE------------------------------- placebo) are: somnolence, dizziness, fatigue, nausea, and exacerbated ROZEREM is indicated for the treatment of insomnia characterized by insomnia. (6.1) difficulty with sleep onset. (1) To report SUSPECTED ADVERSE REACTIONS, contact Takeda -----------------------DOSAGE AND ADMINISTRATION------------------------ Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1- • Adult dose: 8 mg taken within 30 minutes of going to bed. (2.1) 800-FDA-1088 or www.fda.gov/medwatch. • Should not be taken with or immediately after a high-fat meal. (2.1) • Total daily dose should not exceed 8 mg. (2.1) --------------------------------DRUG INTERACTIONS-------------------------------- • Rifampin (strong CYP enzyme inducer): Decreases exposure to and ----------------------DOSAGE FORMS AND STRENGTHS---------------------- effects of ramelteon.
    [Show full text]
  • Escitalopram Oxalate
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------WARNINGS AND PRECAUTIONS------------­ These highlights do not include all the information Clinical Worsening/Suicide Risk: Monitor for clinical needed to use Lexapro® safely and effectively. See full worsening, suicidality and unusual change in behavior, prescribing information for Lexapro®. especially, during the initial few months of therapy or at times of dose changes (5.1). Lexapro® (escitalopram oxalate) Tablets Serotonin Syndrome: Serotonin syndrome has been Lexapro® (escitalopram oxalate) Oral Solution reported with SSRIs and SNRIs, including Lexapro, both Initial U.S. Approval: 2002 when taken alone, but especially when co-administered WARNING: Suicidality and Antidepressant Drugs with other serotonergic agents (including triptans, See full prescribing information for complete boxed tricyclic antidepressants, fentanyl, lithium, tramadol, warning. tryptophan, buspirone, amphetamines, and St. John’s Increased risk of suicidal thinking and behavior in Wort). If such symptoms occur, discontinue Lexapro and children, adolescents and young adults taking initiate supportive treatment. If concomitant use of antidepressants for major depressive disorder (MDD) Lexapro with other serotonergic drugs is clinically and other psychiatric disorders. Lexapro is not warranted, patients should be made aware of a potential approved for use in pediatric patients less than 12 increased risk for serotonin syndrome, particularly during years of age (5.1). treatment initiation and dose increases (5.2). Discontinuation of Treatment with Lexapro: A gradual reduction in dose rather than abrupt cessation is -------------------RECENT MAJOR CHANGES---------------- recommended whenever possible (5.3). Warnings and Precautions (5.2) 1/2017 Seizures: Prescribe with care in patients with a history of seizure (5.4). --------------INDICATIONS AND USAGE------------------- Activation of Mania/Hypomania: Use cautiously in Lexapro® is a selective serotonin reuptake inhibitor (SSRI) patients with a history of mania (5.5).
    [Show full text]
  • Escitalopram
    Application for Inclusion to the 21st Expert Committee on the Selection and Use of Essential Medicines: ESCITALOPRAM December 7, 2018 Submitted by: Iona K. Machado, M.D., Csilla Lippert, M.D.,Ph.D.., Ricardo Lozano, M.D., Michael J. Ostacher, M.D., MPH, MMSc Primary Contact: Iona K. Machado, M.D., +1-650-721-4421, [email protected] 1 TABLE OF CONTENTS Page 3 1. Summary Statement Page 4 2. Focal Point Person in WHO Page 5 3. Name of the Submitting Organization Page 6 4. International Proprietary Name Page 7 5. Formulation Proposed for Inclusion & Current Availability Page 10 6. Listing Requested Page 11 7. Treatment Details Page 16 8. Public Health Relevance Page 19 9. Comparative Efficacy Page 23 10. Comparative Safety Page 43 11. Comparative Cost-Effectiveness Page 50 12. Regulatory Status Page 51 13. Pharmacoepial Standards Page 52 14. References Page 61 APPENDIX: Letters of Support 2 1. Summary statement of the proposal for inclusion of escitalopram This is a proposal to include escitalopram on the core WHO Model List of Essential Medications (EML) to treat adults age 18+ with major depressive disorder. The latest EML includes a member of the tricyclic antidepressant (TCA) class, amitriptyline, and one member of the selective serotonin reuptake inhibitor (SSRI) class, fluoxetine. We provide a review of evidence on efficacy, safety, availability, and cost-effectiveness of escitalopram, another member of the SSRI class, for the treatment of depression in adults. Escitalopram was first introduced to market in 2002 in the United States and has become a generically available product as of 2012.
    [Show full text]
  • Antidepressants: Mechanism of Action, Toxicity and Possible Amelioration
    Journal of Applied Biotechnology & Bioengineering Research Article Open Access Antidepressants: mechanism of action, toxicity and possible amelioration Abstract Volume 3 Issue 5 - 2017 Depression being a state of sadness may be defined as a psychoneurotic disorder Khushboo, Sharma B characterised by mental and functional activity, sadness, reduction in activity, Department of Biochemistry, University of Allahabad, India difficulty in thinking, loss of concentration, perturbations in appetite, sleeping, and feelings of dejection, hopelessness and generation of suicidal tendencies. It Correspondence: B Sharma, Department of Biochemistry, is a common and recurrent disorder causing significant morbidity and mortality University of Allahabad, Allahabad 211002, UP, India, worldwide. The antidepressant compounds used against depression are reported to Email [email protected] be used also for treating pain, anxiety syndromes etc. They have been grouped in five different categories such as Received: June 29, 2017 | Published: September 01, 2017 i. Tricyclic antidepressants (TCAs) ii. Selective serotonin-reuptake inhibitors (SSRIs) iii. Monoamine oxidase inhibitors (MAOIs) iv. Serotonin-norepinephrine reuptake inhibitor (SNRI) and v. Non-TCA antidepressants based on their mode of action. Most of the antidepressants have been reported to possess adverse effects on the health of users. The present review article focuses on an updated current of antidepressants, their mechanism of actions, pathophysiology of these compounds, their side effects and
    [Show full text]
  • Selective Serotonin Reuptake Inhibitors and Adverse Effects: a Narrative Review
    Review Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review Amber N. Edinoff 1,*, Haseeb A. Akuly 1 , Tony A. Hanna 1, Carolina O. Ochoa 2, Shelby J. Patti 2, Yahya A. Ghaffar 2, Alan D. Kaye 3, Omar Viswanath 4,5,6, Ivan Urits 3,7 , Andrea G. Boyer 8, Elyse M. Cornett 3 and Adam M. Kaye 9 1 Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA 71103, USA; [email protected] (H.A.A.); [email protected] (T.A.H.) 2 School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA; [email protected] (C.O.O.); [email protected] (S.J.P.); [email protected] (Y.A.G.) 3 Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA; [email protected] (A.D.K.); [email protected] (I.U.); [email protected] (E.M.C.) 4 College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA; [email protected] 5 Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE 68124, USA 6 Valley Anesthesiology and Pain Consultants—Envision Physician Services, Phoenix, AZ 85004, USA 7 Southcoast Physicians Group Pain Medicine, Southcoast Health, Wareham, MA 02571, USA 8 Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29464, USA; [email protected] 9 Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-(318)-675-8969 Citation: Edinoff, A.N.; Akuly, H.A.; Hanna, T.A.; Ochoa, C.O.; Patti, S.J.; Abstract: Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the Ghaffar, Y.A.; Kaye, A.D.; Viswanath, global population.
    [Show full text]